CH3 Orthogonal Mutations for Specific Antibody Heterodimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to efficiently drive specific heterodimerization of multiple polypeptide chains, particularly in the assembly of multivalent, multispecific antibody constructs, requiring improved protein:protein interactions to favor heterodimerization over homodimerization.
Innovation Solution
Engineering orthogonal mutations, such as knob-in-hole, cascade, and charge-pair mutations, in CH3 domains to enhance the affinity and specificity of heterodimerization, facilitating high-fidelity association of polypeptides in antibody constructs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple polypeptide chains are assembled to form multivalent multispecific antibodies, then the therapeutic functionality and antigen binding capability are improved, but the complexity of achieving specific heterodimerization over homodimerization increases significantly
Solution Approach 1:
The patent applies local quality by introducing specific orthogonal mutations at defined positions within the CH3 domains of antibody heavy chains. Each mutation creates a localized interaction interface that is unique to a specific heterodimer pair, allowing different regions of the antibody to have different binding specificities. This enables precise control over which heavy chains associate together in multivalent constructs.
Solution Approach 2:
The patent employs asymmetry through orthogonal mutations that create non-reciprocal or differently weighted interactions between heavy chains. By mutating specific residues (such as positions 370, 357, 364, 405, 407) to create knobs or holes with specific geometric and electrostatic properties, the patent ensures that heterodimerization interfaces are asymmetric and chain-specific, preventing homodimer formation while promoting desired heterodimer pairs.
2Manufacturing precision
If orthogonal mutations are introduced to drive specific heterodimerization, then the assembly fidelity of polypeptide chains is improved, but the protein structure complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies parameter changes by systematically modifying specific amino acid parameters at defined positions in the CH3 domain. Mutations include creating hydrophobic knobs (e.g., V370L, V370I), introducing charged residues for electrostatic interactions (e.g., E357, K370R), and creating steric complements (e.g., F405T, Y407V). These parameter changes at specific positions create predictable and controllable heterodimerization patterns.
Solution Approach 2:
The patent segments the heterodimerization control function into multiple independent mutation sites within the CH3 domain. Rather than relying on a single mutation, the patent distributes orthogonal control across multiple positions (357, 364, 370, 405, 407), where each position contributes a specific interaction element. This segmentation allows independent optimization of each interaction interface and simplifies the engineering process.
3Stability of the object's composition
If multiple orthogonal mutations are combined to enhance heterodimerization specificity, then the stability and fidelity of heterodimeric protein assembly are improved, but the risk of misfolding and aggregation increases
Solution Approach 1:
The patent applies beforehand cushioning by carefully selecting mutation combinations that pre-emptively prevent misfolding and aggregation. The orthogonal mutations are designed to create favorable heterodimer interfaces while maintaining compatibility with the overall protein fold. By pre-testing and selecting specific mutation pairs that have been shown to assemble correctly, the patent cushions against the formation of misfolded or aggregated species before they can occur.
Data Source
AI summary
Heterodimerizing domains with orthogonal mutations that drive heterodimerization, in particular heterodimerizing antibody CH3 domains, heterodimeric polypeptides comprising such heterodimerizing domains, and antibody constructs comprising such heterodimeric polypeptides, are provided.